Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Intercontinental Wealth Advisors LLC

Intercontinental Wealth Advisors LLC decreased its stake in Anika Therapeutics, Inc. (NASDAQ:ANIKGet Rating) by 4.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,257 shares of the biotechnology company’s stock after selling 730 shares during the period. Intercontinental Wealth Advisors LLC owned 0.10% of Anika Therapeutics worth $358,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ANIK. Point72 Hong Kong Ltd acquired a new stake in shares of Anika Therapeutics in the 4th quarter worth $39,000. Nisa Investment Advisors LLC purchased a new position in shares of Anika Therapeutics in the 1st quarter valued at about $29,000. Connors Investor Services Inc. increased its holdings in Anika Therapeutics by 24.2% during the 4th quarter. Connors Investor Services Inc. now owns 7,699 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 1,500 shares in the last quarter. Riverwater Partners LLC increased its holdings in Anika Therapeutics by 36.0% during the 1st quarter. Riverwater Partners LLC now owns 12,370 shares of the biotechnology company’s stock valued at $311,000 after acquiring an additional 3,274 shares in the last quarter. Finally, Yousif Capital Management LLC purchased a new position in Anika Therapeutics during the 4th quarter valued at about $446,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Anika Therapeutics Stock Performance

NASDAQ:ANIK opened at $22.68 on Friday. The firm has a 50-day moving average price of $22.51 and a two-hundred day moving average price of $25.09. Anika Therapeutics, Inc. has a twelve month low of $19.95 and a twelve month high of $45.81.

Anika Therapeutics (NASDAQ:ANIKGet Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.06. Anika Therapeutics had a negative net margin of 7.26% and a negative return on equity of 1.96%. During the same quarter in the prior year, the company posted $0.09 earnings per share. On average, equities analysts anticipate that Anika Therapeutics, Inc. will post -0.55 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP David Colleran bought 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average cost of $21.37 per share, with a total value of $32,055.00. Following the completion of the transaction, the executive vice president now owns 9,867 shares of the company’s stock, valued at $210,857.79. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 3.03% of the stock is owned by corporate insiders.

Anika Therapeutics Profile

(Get Rating)

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.

See Also

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIKGet Rating).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.